U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30ClN7O4S
Molecular Weight 548.0594
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDOXABAN

SMILES

CN(C)C(=O)[C@@]1([H])CC[C@@]([H])([C@@]([H])(C1)NC(=O)c2nc3CCN(C)Cc3s2)NC(=O)C(=O)Nc4ccc(cn4)Cl

InChI

InChIKey=HGVDHZBSSITLCT-JLJPHGGASA-N
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H30ClN7O4S
Molecular Weight 548.0594
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18624979

Edoxaban (DU-176b, trade names Savaysa, Lixiana) is a selective factor Xa inhibitor reduces thrombin generation and thrombus formation and is an orally bioavailable anticoagulant drug. It was developed by Daiichi Sankyo to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism following 5-10 days of initial therapy with a parenteral anticoagulant.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.561 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
SAVAYSA

Approved Use

SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1)

Launch Date

1.42067525E12
Primary
SAVAYSA

Approved Use

SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1)

Launch Date

1.42067525E12
Primary
SAVAYSA

Approved Use

SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) (1.1) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) (1.1) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant (1.2) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Clinical Studies (14.1)

Launch Date

1.42067525E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
305 ng/mL
60 mg 2 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
507 ng/mL
90 mg 1 times / day multiple, oral
dose: 90 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
649 ng/mL
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
302 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
312 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
33.5 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
375 ng/mL
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
409 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
487 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
152 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1805 ng × h/mL
60 mg 2 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2806 ng × h/mL
90 mg 1 times / day multiple, oral
dose: 90 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
3682 ng × h/mL
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1779 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1781 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
259 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2680 ng × h/mL
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2789 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4322 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
993 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.44 h
60 mg 2 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9.2 h
90 mg 1 times / day multiple, oral
dose: 90 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9.75 h
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
8.9 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.75 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
5.79 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.3 h
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.56 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.7 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.92 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EDOXABAN TOSYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
45%
unknown, unknown
EDOXABAN TOSYLATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / day steady, oral
Highest studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: steady
Dose: 120 mg, 1 times / day
Sources:
healthy, 18 - 55 years
n = 9
Health Status: healthy
Age Group: 18 - 55 years
Sex: M
Population Size: 9
Sources:
150 mg single, oral
Highest studied dose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
healthy, 18 - 55 years
n = 9
Health Status: healthy
Age Group: 18 - 55 years
Sex: M
Population Size: 9
Sources:
60 mg 2 times / day steady, oral
Highest studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
healthy, 18 - 55 years
n = 10
Health Status: healthy
Age Group: 18 - 55 years
Sex: M
Population Size: 10
Sources:
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Sources:
unknown, 57 years
n = 1
Health Status: unknown
Age Group: 57 years
Sex: F
Population Size: 1
Sources:
Other AEs: Activated partial thromboplastin time prolonged...
Other AEs:
Activated partial thromboplastin time prolonged
Sources:
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Ischemic stroke...
AEs leading to
discontinuation/dose reduction:
Ischemic stroke
Sources:
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 5417
Health Status: unhealthy
Population Size: 5417
Sources:
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (3.9%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Activated partial thromboplastin time prolonged
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Sources:
unknown, 57 years
n = 1
Health Status: unknown
Age Group: 57 years
Sex: F
Population Size: 1
Sources:
Ischemic stroke Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy
Bleeding 3.9%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 5417
Health Status: unhealthy
Population Size: 5417
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
New oral anticoagulants in atrial fibrillation.
2008 Jan
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
2010 Jul
Factor Xa inhibitors: next-generation antithrombotic agents.
2010 Sep 9
Overview of the new oral anticoagulants: opportunities and challenges.
2015 May
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
2016 Jun
Patents

Sample Use Guides

Nonvalvular Atrial Fibrillation: 60 mg taken orally once daily Deep Vein Thrombosis and Pulmonary Embolism: 60 mg taken orally once daily following 5 to 10 days of initial therapy with a parenteral anticoagulant. If a dose of is missed, the dose should be taken as soon as possible on the same day. Dosing should resume the next day according to the normal dosing schedule. The dose should not be doubled to make up for a missed dose.
Route of Administration: Oral
In vitro, FXa inhibition, specificity and anticoagulant activities were examined. DU-176b (Edoxaban) inhibited FXa with Ki values of 0.561 nm for free FXa, 2.98 nm for prothrombinase, and exhibited >10 000-fold selectivity for FXa. In human plasma, DU-176b doubled prothrombin time and activated partial thromboplastin time at concentrations of 0.256 and 0.508 microm, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:01:08 UTC 2021
Edited
by admin
on Sat Jun 26 12:01:08 UTC 2021
Record UNII
NDU3J18APO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EDOXABAN
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
N-(5-CHLOROPYRIDIN-2-YL)-N'-((1S,2R,4S)-4-(N,N-DIMETHYLCARBAMOYL)-2-(5-METHYL-4,5,6,7- TETRAHYDRO(1,3)THIAZOLO(5,4-C)PYRIDINE-2-CARBOXAMIDO)CYCLOHEXYL)OXAMIDE
Systematic Name English
EDOXABAN [MART.]
Common Name English
EDOXABAN [MI]
Common Name English
EDOXABAN [USAN]
Common Name English
DU-176
Code English
ETHANEDIAMIDE, N1-(5-CHLORO-2-PYRIDINYL)-N2-((1S,2R,4S)-4- ((DIMETHYLAMINO)CARBONYL)- 2-(((4,5,6,7-TETRAHYDRO-5-METHYLTHIAZOLO(5,4-C)PYRIDIN-2-YL)CARBONYL)AMINO)CYCLOHEXYL)-
Common Name English
EDOXABAN [INN]
Common Name English
EDOXABAN [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AF03
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
NDF-RT N0000175637
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
Code System Code Type Description
JAPANESE REVIEW
LIXIANA
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY APPROVED APRIL 2011
JAPANESE REVIEW
LIXIANA
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY APPROVED APRIL 2011
MERCK INDEX
M4832
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY Merck Index
INN
8982
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
RXCUI
1599538
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4897
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
MESH
C552171
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
WIKIPEDIA
Edoxaban
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL1269025
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
LACTMED
Edoxaban
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
EVMPD
SUB32701
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
DRUG BANK
DB09075
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
IUPHAR
7575
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
CAS
480449-70-5
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
NCI_THESAURUS
C96539
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
FDA UNII
NDU3J18APO
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
EPA CompTox
480449-70-5
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
PUBCHEM
10280735
Created by admin on Sat Jun 26 12:01:09 UTC 2021 , Edited by admin on Sat Jun 26 12:01:09 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL; PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE ACTIVE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
MINOR
PLASMA; URINE
METABOLITE -> PARENT
MINOR
PLASMA; URINE
METABOLITE ACTIVE -> PARENT
FECAL; PLASMA
METABOLITE -> PARENT
MINOR
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC